Reference Centre for Rare Skin Diseases, Dermatology Department (CRMRP), Larrey University Hospital, 24, Chemin de Pouvourville TSA 30030, 31059, Toulouse, France.
Department of Clinical Pharmacology, CIC1436, University Hospital, Toulouse, France.
Orphanet J Rare Dis. 2021 Feb 18;16(1):93. doi: 10.1186/s13023-021-01710-x.
Patients with Hailey-Hailey and Darier diseases present with disabling inflammatory lesions located in large skin folds, which are often exacerbated or induced by sweating. Quality of life is highly impaired because of pain and recurrent skin infections. An improvement in skin lesions after botulinum toxin A injections has previously been reported in some patients but no prospective interventional studies are available. The aim of this open-label, 6-month, interventional pilot study (NCT02782702) was to evaluate the effectiveness and safety of botulinum toxin A for patients with moderate to very severe skin lesions located in folds.
Thirty patients (26 Hailey-Hailey/4 Darier) were included. Botulinum toxin A proved effective within the first month in two-thirds of patients, taking all study parameters (itchiness, cutaneous pain, sweating and odour, infections, psychosocial impairment and quality of life) into account and persisted during the 6-month follow-up period. No patient was classed as a BtxA non-responder, but 11 (37%) Hailey-Hailey patients (the most severe ones), experienced a relapse during the study. No serious side effects were reported. Mild transient clear fluid discharge at the site of the injections was reported for 27% of patients.
Botulinic toxin seems to be an effective and safe treatment for Hailey-Hailey and Darier diseases. Nevertheless, it may prove insufficient for the severest of Hailey-Hailey cases and could be considered as supplementary to other conventional treatments. Further studies are required to confirm our results on larger Darier cohorts.
患有 Hailey-Hailey 病和 Darier 病的患者会出现位于大皮肤褶皱处的致残性炎症性病变,这些病变通常会因出汗而加重或诱发。由于疼痛和反复的皮肤感染,生活质量受到严重影响。先前有报道称,一些患者在接受肉毒杆菌毒素 A 注射后,皮肤病变有所改善,但尚无前瞻性干预性研究。本开放性标签、6 个月、干预性试点研究(NCT02782702)的目的是评估肉毒杆菌毒素 A 对位于褶皱处的中度至重度皮肤病变患者的有效性和安全性。
共纳入 30 例患者(26 例 Hailey-Hailey/4 例 Darier)。肉毒杆菌毒素 A 在三分之二的患者中在第一个月内有效,考虑到所有研究参数(瘙痒、皮肤疼痛、出汗和气味、感染、心理社会障碍和生活质量),并在 6 个月的随访期间持续有效。没有患者被归类为 BtxA 无应答者,但 11 例(37%) Hailey-Hailey 患者(病情最严重的患者)在研究期间复发。未报告严重的不良反应。27%的患者报告在注射部位出现轻微短暂的透明液体排出。
肉毒毒素似乎是 Hailey-Hailey 病和 Darier 病的一种有效且安全的治疗方法。然而,对于病情最严重的 Hailey-Hailey 病例,它可能证明是不够的,可以考虑将其作为其他常规治疗的补充。需要进一步的研究来证实我们在更大的 Darier 队列中的结果。